RxDoctor Payments Data

Mary Wilson, NP

Nurse Practitioner · Cedar Springs, MINPI 1063431708

Payments from drug & device makers

$1,647in general payments, 2019–2025

Across 16 payments — averaging $102.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sanofi-aventis U.S. LLC$1K
  • Abbott$178
  • Tandem Diabetes Care, Inc.$71
  • AstraZeneca$66
  • Ascensia Diabetes Care US Inc.$41
  • BETA Bionics, Inc.$33
  • plus $41 from 2 others

What the payments were for

  • Consulting fees$76747%
  • Food & beverage$86152%
  • Education$191%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,647 in reported general payments places this provider in the 85th percentile of 3,351 nurse practitioner providers in Michigan.

See all nurse practitioner providers in Michigan

Medicare billing

Part B allowed, 2024
$21,200
Medicare patients
77
Services billed
338

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide142$195,029
TrulicityDulaglutide92$124,023
OzempicSemaglutide70$115,475
JardianceEmpagliflozin87$112,393
FarxigaDapagliflozin Propanediol112$103,842
Soliqua 100-33Insulin Glargine/Lixisenatide44$66,752
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog49$43,084
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog23$37,356
Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/712$19,559
Lantus SolostarInsulin Glargine,hum.Rec.Anlog40$7,503
Humalog Kwikpen U-100Insulin Lispro22$6,842
Atorvastatin Calcium332$5,379
Novolog FlexpenInsulin Aspart16$4,769
HumalogInsulin Lispro18$3,328
Nano 2nd Gen Pen NeedlePen Needle, Diabetic35$3,225

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity, Humalog$22$322,379252 claims
Boehringer IngelheimJardiance$19$112,39387 claims
AstraZenecaFarxiga$66$103,842112 claims
Sanofi-aventis U.S. LLCSoliqua 100-33$1,216$66,75244 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 3,351 nurse practitioner providers in Michigan.

Other nurse practitioner in Cedar Springs

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →